Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.

Treatment options for patients with radioactive iodine (RaI) refractory metastases of differentiated thyroid carcinoma (DTC) are limited. We studied the effects of the multitarget tyrosine kinase inhibitor sorafenib on the reinduction of RaI uptake and tumor progression.
Open, single center, single arm 26-week prospective phase II study with open-ended extension.
We treated 31 patients with progressive metastatic or locally advanced RaI refractory DTC with sorafenib 400 mg b.i.d. The primary endpoint was reinduction of RaI uptake at 26 weeks. Additional endpoints were the radiological response and the influence of bone metastases.
At 26 weeks of sorafenib therapy, no reinduction of RaI uptake at metastatic sites was observed, but 19 patients (59%) had a clinical beneficial response, eight of whom had a partial response (25%) and 11 had stable disease (34%). Seven patients had progressive disease (22%). Sorafenib was significantly less effective in patients with bone metastases. The estimated median progression free survival was 58 weeks (95% confidence interval, CI, 47-68). In general, thyroglobulin (Tg) response (both unstimulated and TSH stimulated) reflected radiological responses. The median time of the nadir of Tg levels was 3 months. Responses were not influenced by histological subtype, mutational status or other variables. No unusual side effects were observed.
Sorafenib has a beneficial effect on tumor progression in patients with metastatic DTC, but was less effective in patients with bone metastases. Diagnostic whole body scintigraphy did not reveal an effect of sorafenib on the reinduction of RaI uptake.
AuthorsHendrieke Hoftijzer, Karen A Heemstra, Hans Morreau, Marcel P Stokkel, Eleonora P Corssmit, Hans Gelderblom, Karin Weijers, Alberto M Pereira, Maya Huijberts, Ellen Kapiteijn, Johannes A Romijn, Johannes W Smit
JournalEuropean journal of endocrinology / European Federation of Endocrine Societies (Eur J Endocrinol) Vol. 161 Issue 6 Pg. 923-31 (Dec 2009) ISSN: 1479-683X [Electronic] England
PMID19773371 (Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Benzenesulfonates
  • Iodine Radioisotopes
  • Phenylurea Compounds
  • Pyridines
  • Niacinamide
  • Thyroglobulin
  • sorafenib
  • Protein-Tyrosine Kinases
  • Adenocarcinoma, Follicular (drug therapy, radiotherapy)
  • Aged
  • Aged, 80 and over
  • Benzenesulfonates (adverse effects, therapeutic use)
  • Bone Neoplasms (drug therapy, radiotherapy, secondary)
  • Disease-Free Survival
  • Female
  • Humans
  • Iodine Radioisotopes (therapeutic use)
  • Male
  • Middle Aged
  • Niacinamide (analogs & derivatives)
  • Phenylurea Compounds
  • Protein-Tyrosine Kinases (antagonists & inhibitors)
  • Pyridines (adverse effects, therapeutic use)
  • Thyroglobulin (metabolism)
  • Thyroid Neoplasms (drug therapy, pathology, radiotherapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: